Overview

Gender

male

Denis O’Shaughnessy has more than 25 years of clinical, pharmaceutical, and ophthalmology experience.

Prior to joining Oraya, he was Senior Vice President of Clinical Development at OPKO, Inc., and before that, Dr. O’Shaughnessy was a founding member of Eyetech Pharmaceuticals, responsible for overseeing the Macugen® development program, which resulted in the completion and successful marketing approval of this pioneering wet AMD anti-VEGF drug in just under four years.

Dr. O’Shaughnessy has worked for a number of pharmaceutical companies, including Hoffman-La Roche, where he established the first-ever clinical drug research program in the retinal field, Sandoz (Novartis), Xoma, and Celltech.

While at Celltech, he headed up its Clinical Research Department. Dr. O’Shaughnessy began his career as a clinical research manager in 1984, with American Cyanamid’s European regional office in London.

Dr. O’Shaughnessy received a Bachelor of Science degree in physiology and biochemistry from Queen Elizabeth College London and a PhD in physiology from the Royal Postgraduate Medical School London.